TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06231069

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Description: 12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of short-duration mixed endurance and resistance exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 12 weeks of short-duration mixed endurance and resistance exercise.
Study: NCT06759922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tab Metformin + Tab Empagliflozin
Description: Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tab Metformin +Tab Sitagliptin
Description: Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
Description: Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.
Study: NCT05877027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Diclofenac
Description: They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich-Plasma (PRP)
Description: 8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
Study: NCT05305547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Administered as a round tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a round tablet.
Study: NCT05463263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP938
Description: Small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP938
Description: Small molecule
Study: NCT06524349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed knee extender device
Description: Participants will receive a 3D printed knee extender device with sealed water bottles and an at-home rehabilitation program designed to be used with the 3D printed knee extender device.
Study: NCT04462302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based pain coping skills program
Description: The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
Study: NCT06302491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules
Description: Administer AND017 capsules once per day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules
Description: Administer AND017 capsules once per day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules
Description: Administer AND017 capsules once per day (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AND017 Placebo
Description: Administer AND017 matching placebo capsules once per day (QD)
Study: NCT05543837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Patients will receive a fixed dose of capsaicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Patients will receive a fixed dose of capsaicin
Study: NCT05650125

Intervention type: OTHER
Intervention: Biosampling
Description: Biosampling of blood/tumour/adjacent normal tissue
Study: NCT05633134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography and precision preoperative embolization
Description: Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriography
Description: Arteriography of pelvic tumors 0-24 hours prior to surgery.
Study: NCT04756596

Intervention type: DIAGNOSTIC_TEST
Intervention: DDVIT testing
Description: One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: ETDRS testing
Description: The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
Study: NCT04689347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
Study: NCT05026164

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHI-202
Description: Blend of cannabinoids \& other ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CHI-101
Description: Placebo
Study: NCT01916031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT04949607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin fructooligosaccharide
Description: Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin fructooligosaccharide
Description: Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
Study: NCT05651399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
Study: NCT05505071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANTE SPACE sequence
Description: investigational MRI sequence less than 15 minutes
Study: NCT04820933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100 Mg
Description: Doravirine 100 Mg orally dail
Study: NCT04689347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 165 mg/sqm intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: leucovorin 200 mg/sqm intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
Study: NCT06305520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational medical device (SkinPlus-HYAL Implant Lidocaine)
Description: \* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)
Description: \* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
Study: NCT06468748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
Study: NCT05962502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab and irinotecan
Description: chemotherapy plus targeted therapy
Study: NCT05263440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
Study: NCT05516459

Intervention type: BIOLOGICAL
Intervention: Pfizer BNT162b2 Vaccine
Description: The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
Study: NCT04476355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Select and Tailor implementation interventions
Description: Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
Study: NCT05717452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry drink
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: 22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
Study: NCT04894084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP321
Description: The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
Study: NCT05072548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The ABCs of SLEEPING
Description: The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on.
Study: NCT05669846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy. The FMT consists of introducing normal bacterial flora contained in the stool collected from a donor into the small intestine. In this case, the donors are patients with advanced metastatic non-small cell lung cancer (NSCLC) who have undergone PD-1 therapy (nivolumab or pembrolizumab) and are currently in a durable remission that is ongoing. The FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
Study: NCT05252455

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pelvic and abdominal mechanics exercise
Description: starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)
Study: NCT03624413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care transition from pediatric to adult care for HIV.
Study: NCT04781595

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon
Description: A single dose of watermelon powder containing 3g of L-citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot
Description: A single dose of beetroot powder containing 8 mmol of nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon + beetroot
Description: A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of maltodextrin
Study: NCT06357910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2303
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2303
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take 1 tablet once per period
Study: NCT04330768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF pulp capping
Description: PRF is injected in the site of exposure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulp capping
Description: conventional pulp capping procedure
Study: NCT04573803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
Study: NCT06513546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLL001 or placebo daily subcutaneous injections
Description: PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLL001 or placebo daily subcutaneous injections
Description: PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLL001 or placebo daily subcutaneous injections
Description: PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
Study: NCT05380791

Intervention type: OTHER
Intervention: Follow-up visits
Description: Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations

Intervention type: OTHER
Intervention: Follow-up visits
Description: Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
Study: NCT05287282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECAR application
Description: Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TECAR application
Description: Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
Study: NCT06261775

Intervention type: OTHER
Group type: OTHER
Intervention: Red meat-based meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red meat-based meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Lacto-ovo-vegetarian meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.